Success Metrics

Completion Rate
0%(0/2)
Active Trials
0(0%)
Terminated
2(50%)

Phase Distribution

Ph phase_1
1
25%
Ph phase_2
3
75%

Phase Distribution

1

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
3(75.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 4 finished

Non-Completion Rate

100.0%

4 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Terminated(4)

Detailed Status

Terminated2
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (25.0%)
Phase 23 (75.0%)

Trials by Status

terminated250%
withdrawn250%

Recent Activity

0 active trials
Showing 4 of 4
withdrawnphase_2

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

NCT00227773
terminatedphase_2

Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy

NCT00390364
terminatedphase_2

Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery

NCT00258297
withdrawnphase_1

Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer

NCT00268255

Clinical Trials (4)

Showing 4 of 4 trials
NCT00227773Phase 2

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

Withdrawn
NCT00390364Phase 2

Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy

Terminated
NCT00258297Phase 2

Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery

Terminated
NCT00268255Phase 1

Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer

Withdrawn

All 4 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
4